Pd48-05 Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access Setting: A Propensity Scored Matched Analysis

You have accessJournal of UrologyBladder Cancer: Non-invasive III (PD48)1 May 2024PD48-05 USE OF BLUE LIGHT CYSTOSCOPY AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS AND OUTCOMES IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS Sanjay K. Das, Ali Nasrallah, Lin Gu, Claire Trustram Eve, Joshua Parrish, Amanda De Hoedt, Chad McKee, William Aronson, Stephen J. Freedland, and Stephen B. Williams Sanjay K. DasSanjay K. Das , Ali NasrallahAli Nasrallah , Lin GuLin Gu , Claire Trustram EveClaire Trustram Eve , Joshua ParrishJoshua Parrish , Amanda De HoedtAmanda De Hoedt , Chad McKeeChad McKee , William AronsonWilliam Aronson , Stephen J. FreedlandStephen J. Freedland , and Stephen B. WilliamsStephen B. Williams View All Author Informationhttps://doi.org/10.1097/01.JU.0001008712.53259.7d.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recent studies have shown conflicting evidence regarding the utility of blue light cystoscopy (BLC) and impact on oncologic outcomes. We describe recurrence outcomes among a predominantly high-risk non-muscle invasive bladder cancer (NMIBC) patient cohort that underwent BLC vs. white light cystoscopy (WLC) in the Veterans Affairs Healthcare System, the largest equal access setting in the US. METHODS: We abstracted a total of 965 NMIBC patients within the Veteran Affairs (VA) that underwent BLC versus WLC from January 1, 1991 to January 31, 2023. After propensity score matching, a total of 337 BLC and 337 WLC patients were included. We estimated recurrence-free survival rates following either BLC or WLC from date of bladder cancer diagnosis using the Kaplan-Meier method and calculated the hazard ratio (HR) from proportional hazard ratio Cox model adjusting for demographics and clinical characteristics. RESULTS: Median follow-up was 3.4 years and 2.0 years for the BLC and WLC cohorts, respectively. 393 (58%) patients received BCG at any point during the study. The risk of recurrence was significantly lower following BLC (multivariable-adjusted HR 0.67, 95% Confidence Interval (CI) 0.51-0.89, p=0.006) than WLC. High-risk (CIS, T1, or Ta high grade) NMIBC patients had significantly improved recurrence-free survival following BLC (HR 0.69, 95%CI 0.50-0.97, p=0.03) and among those that underwent BCG (HR 0.69, 95%CI 0.49-0.98, p=0.04). High-risk NMIBC patients had significantly higher overall survival following BLC (HR 0.51, 95%CI 0.31-0.85, p=0.01) and among those that received BCG (HR 0.53, 95%CI 0.32-0.88, p=0.01), respectively. CONCLUSIONS: In this study from the VA HCS, the largest equal access setting in the US, we observed significantly decreased risk of recurrence in patients who underwent BLC versus only WLC. Download PPT Source of Funding: This study was conducted with the financial support of Photocure, Inc. Dr. Das was supported by the Patient-Centered Outcomes Research Training in Urologic and Gynecologic Cancers (PCORT UroGynCan): T32CA251072 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e989 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sanjay K. Das More articles by this author Ali Nasrallah More articles by this author Lin Gu More articles by this author Claire Trustram Eve More articles by this author Joshua Parrish More articles by this author Amanda De Hoedt More articles by this author Chad McKee More articles by this author William Aronson More articles by this author Stephen J. Freedland More articles by this author Stephen B. Williams More articles by this author Expand All Advertisement PDF downloadLoading ...